Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights

Medical Decision Making

Volumn 28, Issue 1, 2008, Pages 66-89

  Mortimer, Duncan ^a,b   Segal, Leonie ^a  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Health status; Outcome assessment (health care); Quality adjusted life years; Resource allocation

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALGORITHM; ASTHMA; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DYSTHYMIA; HEALTH CARE; HEALTH CARE PERSONNEL; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LOW BACK PAIN; LUNG GRAFT REJECTION; MENTAL DISEASE; MORTALITY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; QUALITATIVE VALIDITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; STROKE; STRUCTURED QUESTIONNAIRE; SYSTEMATIC REVIEW; VALIDATION STUDY; VEIN DISEASE;

ALGORITHMS; HEALTH CARE RATIONING; HEALTH STATUS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; VICTORIA;

EID: 38349114873     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X07309642     Document Type: Review

References (67)

1. Ware J., Snow K., Kosinski M., Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Centre ; 1993.
2. Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2 nd ed. Philadelphia: Lippincott-Raven ; 1996. p 191 - 201.
3. Neumann PJ, Goldie SJ, Weinstein MC Preference-based measures in economic evaluation in health care. Annu Rev Public Health. 2000 ; 21: 587 - 611.
4. Gold M., Siegel J., Russell L., Weistein MC Cost-Effectiveness in Health and Medicine. Melbourne, Australia: Oxford University Press ; 1996.
5. Hawthorne G., Richardson J., Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health related quality of life. Qual Life Res. 1999 ; 8: 209 - 24.
6. Fryback DG, Dasbach EJ, Klein R., et al. Health assessment by SF36, quality of well-being index and time-tradeoffs: predicting one measure from another [abstract]. Med Decis Making. 1992 ; 12: 348.
7. Tsevat J., Solzan JG, Tolan KK, et al. Health status and utilities of HIV+ and primary care patients [abstract]. Clin Res. 1992 ; 40: 569A.
8. Revicki DA Relationship between health utility and psychometric health status measures. Med Care. 1992 ; 30 (suppl): 274 - 82. 9. Bosch JL, Hunink Mgm The relationship between descriptive and valuational quality-of-life measures in patients with intermittent claudication. Med Decis Making. 1996 ; 16: 217 - 25.
9. Bult JR, Bosch JL, Hunink MGM Heterogeneity in the relationship between the standard-gamble utility measures and health-status dimensions. Med Decis Making. 1996 ; 16: 266 - 33.
10. Fryback DG, Lawrence WF, Martin PA, Klein R., Klein BE Predicting quality of well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making. 1997 ; 17: 1 - 9.
11. McEwan P., Morrissey M., Currie CJ An improved model to calculate utility scores from SF36 data. Value Health. 2003 ; 6: 302 - 3.
12. McEwan P., Kind P., Dixon S., Currie SJ Using an artificial neural network to predict utility scores from SF36 data. Value Health. 2004 ; 7: 305.
13. Mortimer D., Segal L., Harris A., Hawthorne G. Item-based versus subscale-based mappings from the SF36 to a preference-based quality of life measure. Value Health. 2007 ; 10: 398 - 407.
14. Nichol MB, Sengupta N., Globe D. Evaluating quality-adjusted life years: estimation of the HUI2 from the SF-36. Med Decis Making. 2001 ; 21: 105 - 12.
15. Segal L., Day SE, Chapman AB, Osborne RH Can we reduce the burden from osteoarthritis? An evidence-based priority-setting model. Med J Aust. 2004 ; 180: S11 - 7.
16. Shmueli A. The SF36 profile and health-related quality of life: an interpretive analysis. Qual Life Res. 1998 ; 7: 187 - 95.
17. Shmueli A. Subjective health status and health values in the general population. Med Decis Making. 1999 ; 19: 128 - 40.
18. Shmueli A. The relationship between the visual analogue scale and the SF-36 scales in the general population: an update. Med Decis Making. 2004 ; 24: 61 - 3.
19. Tsevat J., Solzan JG, Kuntz KM, et al. Health values of patients infected with human immunodeficiency virus: relationship to mental health and physical functioning. Med Care. 1996 ; 34: 44 - 57.
20. Yu AP, Yu YF, Nichol MB Bridging beyond regression-artificial neural network in mapping from SF-36 to health utility. Value Health. 2005 ; 8: 384.
21. Yu AP, Yu YF, Nichol MB Are relationships between SF36 subscales and health utility merely linear? Paper presented at the 26th annual meeting of the Society for Medical Decision Making, Buckhead, Australia, 17-20 October 2004.
22. Franks P., Lubetkin EI, Gold ME, Tancredi DJ, Jia H. Mapping the SF-12 to the EuroQol EQ-5D Index in a national US sample. Med Decis Making. 2004 ; 24: 247 - 54.
23. Franks P., Lubetkin EI, Gold MR, Tancredi DJ Mapping the SF-12 to preference-based instruments: convergent validity in a low-income, minority population. Med Care. 2003 ; 41: 1277 - 83.
24. Lawrence WF, Fleishman JA Predicting EuroQoL EQ-5D preference scores from the SF-12 health survey in a nationally representative sample. Med Decis Making. 2004 ; 24: 160 - 9.
25. Lundberg L., Johannesson M., Isacson DGL, Borgquist L. The relationship between health-state utilities and the SF12 in a general population. Med Decis Making. 1999 ; 19: 128 - 40.
26. Sengupta N., Nichol MB, Wu J., Globe D. Mapping the SF-12 to the HUI3 and VAS in a managed care population. Med Care. 2004 ; 42: 927 - 37.
27. Sherbourne CD, Unutzer J., Schoenbaum M., et al. Can utility-weighted HRQoL estimates capture health effects of quality improvement for depression? Med Care. 2001 ; 39: 1246 - 59.
28. Brazier JE, Kolotkin RL, Crosby RD, Williams GR Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-lite) instrument from the SF-6D. Value Health. 2004 ; 7: 490 - 8.
29. Clayson DJ, Briggs AH, Sculpher M., De Hert M. Mapping utility scores from the EQ-5D and SF-6D onto the schizophrenia quality of life scale. Value Health. 2004 ; 7: 277.
30. Kulkarni AV Distribution-based and anchor-based approaches provided different interpretability estimates for the Hydrocephalus Outcome Questionnaire. J Clin Epidemiol. 2006 ; 59: 176 - 84.
31. Longworth L., Buxton MJ, Sculpher M., Smith DH Estimating utility data from clinical indicators for patients with stable angina. Eur J Health Econ. 2005 ; 6: 347 - 53.
32. Melsop KA, Boothroyd DB, Hlatky MA Quality of life and time trade-off utility measures in patients with coronary artery disease. Am Heart J. 2003 ; 145: 36 - 41.
33. Paltiel AD, Fuhlbrigge AL, Kitch BT, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the Asthma Policy Model. J Allergy Clin Immunol. 2001 ; 108: 39 - 46.
34. Revicki DA, Weinstein MC, Alderman M. Health Utility and Health Status Outcomes of Antihypertensive Treatment. Washington, DC: Battelle Medical Technology Assessment and Policy Research Center ; 1992.
35. van Doorslaer E., Jones AM Inequalities in self-reported health: validation of a new approach to measurement. J Health Econ. 2003 ; 22: 61 - 87.
36. Viney R., King MT, Savage E., Hall JP Use of the TTU is questionable. Med J Aust. 2004 ; 181: 338.
37. Richardson J. Cost utility analysis: what should be measured? Soc Sci Med. 1994 ; 39: 7 - 21.
38. Gray AM, Rivero-Arias O., Clarke PM Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making. 2006 ; 26: 18 - 29.
39. Dolan P. Modelling valuations for EuroQoL health states. Med Care. 1997 ; 35: 1095 - 1108.
40. Brazier J., Usherwood T., Harper R., Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol. 1998 ; 51: 1115 - 28.
41. Brazier J., Roberts J., Deverill M. The estimation of a preference-based measure from the SF-36. J Health Econ. 2002 ; 21: 271 - 92.
42. Brazier J., Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004 ; 42: 851 - 9.
43. Stratmann-Schoene DS, Kuehn T., Kreienberg R., Leidl R. A preference-based index for the SF12. Health Econ. 2006 ; 15: 553 - 64.
44. Lenert LA, Sherbourne CD, Sugar C., Wells KB Estimation of utilities for the effects of depression from the SF-12. Med Care. 2000 ; 38: 763 - 70.
45. Lenert LA, Sturley AP, Rapaport MH, Chavez S., Mohr PE, Rupnow M. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004 ; 71: 155 - 65.
46. Daley M., Shepard DS, Bury-Maynard D. Changes in quality of life for pregnant women in substance user treatment: developing a quality of life index for the addictions. Subst Use Misuse. 2005 ; 40: 375 - 94.
47. Kind P., Macran S. Eliciting social preference weights for functional assessment of cancer therapy-lung health states. Pharmacoeconomics. 2005 ; 23: 1143 - 53.
48. O'Brien BJ, Spath M., Blackhouse G., Severens JL, Dorian P., Brazier J. A view from the bridge: agreement between the SF-6D utility algorithm and the Health Utilities Index. Health Econ. 2003 ; 12: 975 - 81.
49. Pickard AS, Wang Z., Walton SM, Lee TA Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? Health Qual Life Outcomes. 2005 ; 3 (1). Available at: www.hqlo.com/content/3/1/11.
50. Sanderson K., Andrews G., Corry J., Lapsley H. Using the effect size to model change in preference values from descriptive health status. Qual Life Res. 2004 ; 13: 1255 - 64.
51. Haby MM, Carter R., Mihalopoulos C., et al. Assessing costeffectiveness-mental health: introduction to the study and methods. Aust N Z J Psychiatry. 2004 ; 38: 569 - 78.
52. Heuzenroeder L., Donnelly M., Haby MM, et al. Cost-effectiveness of psychological and pharmacological interventions for generalised anxiety disorder and panic disorder. Aust N Z J Psychiatry. 2004 ; 38: 602 - 12.
53. Magnus A., Carr V., Mihalopoulos C., Carter R., Vos T. Assessing cost-effectiveness of drug interventions for schizophrenia. Aust N Z J Psychiatry. 2004 ; 39: 44 - 54.
54. Haby MM, Tonge B., Littlefield L., Carter R., Vos T. Cost-effectiveness of cognitive behavioural therapy and selective serotonin reuptake inhibitors for major depression in children and adolescents. Aust N Z J Psychiatry. 2004 ; 38: 579 - 91.
55. Donnelly MM, Haby M., Carter R., Andrews G., Vos T. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder. Aust N Z J Psychiatry. 2004 ; 38: 592 - 601.
56. Gabriel SE, Kneeland TS, Melton LJ, Moncur MM, Ettinger B., Tosteson ANA Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making. 1999 ; 19: 141 - 8.
57. Lee TA, Hollingworth W., Sullivan SD Comparison of directly elicited preferences to preferences derived from the SF-36 in adults with asthma. Med Decis Making. 2003 ; 23: 323 - 34.
58. Bosch JL, Halpern EF, Gazelle GS Comparison of preference-based utilities of the Short-Form 36 Health Survey and Health Utilities Index before and after treatment of patients with intermittent claudication. Med Decis Making. 2002 ; 22: 403 - 9.
59. Hollingworth W., Deyo RA, Sullivan SD, Emerson SS, Gray DT, Jarvik JG The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. Health Econ. 2002 ; 11: 71 - 85.
60. McDonough CM, Grove MR, Tosteson TD, Lurie JD, Hilibrand AS, Tosteson ANA Comparison of EQ-5D, HUI, and SF-36-derived societal health state values among Spine Patient Outcomes Research Trial (SPORT) participants. Qual Life Res. 2005 ; 14: 1321 - 32.
61. Lenert LA, Rupnow MF, Elnitsky C. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health Qual Life Outcomes. 2005 ; 3. Available at: www.hqlo.com/content/3/1/57.
62. Kaplan RM, David K., Ganiats TG Comparison between three methods for imputing utility scores from the SF-36. Paper presented at the 9th annual conference of the International Society for Quality of Life Research (ISOQOL), Orlando, Florida, 30 October-2 November 2002.
63. Kaplan RM, David K., Ganiats TG, Crique MH Comparison of SF-36 to utility transformations in the evaluation of outcomes for patients with venous disease. Paper presented at the 24th annual meeting of the SMDM, Baltimore, 20-23 October 2002.
64. Kaplan RM, Groessl EJ, Sengupta N., Sieber WJ, Ganiats TJ Comparison of measured utility scores and imputed scores from the SF-36 in patients with rheumatoid arthritis. Med Care. 2005 ; 43: 79 - 87.
65. Lobo FS, Gross CR, Matthees BJ Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients. Qual Life Res. 2004 ; 13: 377 - 88.
66. Miller L., Singer M. Relationship of quality of life domains to preference-based measures of quality of life. Value Health. 2004 ; 7: 304.
67. Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from SF-12: US general population preferences in a nationally representative sample. Med Decis Making. 2006 ; 26: 401 - 9.